- Home
- PYN vs SCNX Comparison
PYN vs SCNX Comparison
Compare PYN & SCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYN
- SCNX
- Stock Information
- Founded
- PYN 2002
- SCNX 2010
- Country
- PYN United States
- SCNX United States
- Employees
- PYN N/A
- SCNX N/A
- Industry
- PYN Investment Managers
- SCNX Other Pharmaceuticals
- Sector
- PYN Finance
- SCNX Health Care
- Exchange
- PYN Nasdaq
- SCNX Nasdaq
- Market Cap
- PYN 33.5M
- SCNX 33.6M
- IPO Year
- PYN N/A
- SCNX 2020
- Fundamental
- Price
- PYN $5.91
- SCNX $2.80
- Analyst Decision
- PYN
- SCNX
- Analyst Count
- PYN 0
- SCNX 0
- Target Price
- PYN N/A
- SCNX N/A
- AVG Volume (30 Days)
- PYN 19.9K
- SCNX 10.3K
- Earning Date
- PYN 01-01-0001
- SCNX 03-04-2025
- Dividend Yield
- PYN 5.07%
- SCNX N/A
- EPS Growth
- PYN N/A
- SCNX N/A
- EPS
- PYN N/A
- SCNX 3.55
- Revenue
- PYN N/A
- SCNX N/A
- Revenue This Year
- PYN N/A
- SCNX $1,085.75
- Revenue Next Year
- PYN N/A
- SCNX N/A
- P/E Ratio
- PYN N/A
- SCNX $1.21
- Revenue Growth
- PYN N/A
- SCNX 166.67
- 52 Week Low
- PYN $4.84
- SCNX $2.61
- 52 Week High
- PYN $6.60
- SCNX $44.56
- Technical
- Relative Strength Index (RSI)
- PYN 65.73
- SCNX N/A
- Support Level
- PYN $5.79
- SCNX N/A
- Resistance Level
- PYN $5.89
- SCNX N/A
- Average True Range (ATR)
- PYN 0.05
- SCNX 0.00
- MACD
- PYN 0.01
- SCNX 0.00
- Stochastic Oscillator
- PYN 100.00
- SCNX 0.00
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.